Name
Entromed OÜ
Registry code
12349558
VAT number
EE101594033
Type
OÜ - Limited Liability Company
Status
Registered
Foundation date
21.09.2012 (12)
Financial year
01.01-31.12
Capital
2 500.00 €
Activity
64991 - Other financial service activities, except insurance and pension funding n.e.c.
0 €
1 109 954 €
-
-
7 749 355 €
0
Submitted
No tax arrears
14%
14%
Owner | Representative | Beneficial owner | Roles | |
---|---|---|---|---|
Hennadii Rohov 08.01.1979 (45) | 100% - 2 500.00 EUR | Board member | Direct ownership | Founder |
Finexa Legal OÜ 14349143 | - | Person competent to receive procedural documents | - |
2019 10.02.2021 | 2020 07.04.2021 | 2021 18.02.2022 | 2022 07.03.2023 | 2023 15.04.2024 | |
---|---|---|---|---|---|
Total Revenue | 2 129 728 € | 0 € | 0 € | 0 € | 0 € |
Net profit (loss) for the period | 642 676 € | -541 239 € | 226 563 € | 499 070 € | 1 109 954 € |
Profit Margin | 30% | - | - | - | - |
Current Assets | 6 497 429 € | 5 940 029 € | 216 295 € | 284 457 € | 214 010 € |
Fixed Assets | - | - | 5 949 481 € | 6 380 389 € | 7 535 479 € |
Total Assets | 6 497 429 € | 5 940 029 € | 6 165 776 € | 6 664 846 € | 7 749 489 € |
Current Liabilities | 1 594 € | 900 € | 84 € | 84 € | 134 € |
Non Current Liabilities | - | - | - | - | - |
Total Liabilities | - | - | - | - | - |
Share Capital | - | - | - | - | - |
Equity | 6 495 835 € | 5 939 129 € | 6 165 692 € | 6 664 762 € | 7 749 355 € |
Employees | 1 | 0 | 0 | 0 | 0 |
Turnover | State taxes | Labor taxes and payments | Employees | |
---|---|---|---|---|
2024 Q1 | - | - | - | - |
2023 Q4 | - | 777.78 € | 777.78 € | - |
2023 Q3 | - | - | - | - |
2023 Q2 | - | 6 807.06 € | 916.45 € | - |
2023 Q1 | - | - | - | - |
2022 Q4 | - | 3.55 271e-14 € | - | - |
2022 Q3 | - | - | - | - |
2022 Q2 | - | - | - | - |
2022 Q1 | - | - | - | - |
2021 Q4 | - | - | - | - |
2021 Q3 | - | - | - | - |
2021 Q2 | - | - | - | - |
2021 Q1 | - | 2 011.12 € | 2 011.12 € | - |
2020 Q4 | - | 6 151.94 € | 2 866.67 € | - |
2020 Q3 | - | 1 000 € | 1 000 € | - |
2020 Q2 | - | - | - | - |
2020 Q1 | - | - | - | - |